{"id":"experimental-valacyclovir-treatment","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Headache"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"1-5","effect":"Tremor (at high doses)"},{"rate":"1-2","effect":"Confusion or hallucinations (rare, high-dose)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valacyclovir is rapidly metabolized to acyclovir in the body. Acyclovir is phosphorylated by viral thymidine kinase in infected cells, then further phosphorylated to the active triphosphate form, which competitively inhibits viral DNA polymerase and causes chain termination of viral DNA synthesis. This mechanism is selective for herpesvirus-infected cells.","oneSentence":"Valacyclovir is a prodrug that is converted to acyclovir, which inhibits viral DNA polymerase to prevent herpesvirus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:53.660Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Herpes simplex virus (HSV-1 and HSV-2) infection"},{"name":"Varicella-zoster virus (chickenpox and shingles) infection"},{"name":"Cytomegalovirus (CMV) infection prophylaxis in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT01651585","phase":"PHASE4","title":"In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-07","conditions":"Foetuses Infection, Cytomegalovirus (CMV)Infection","enrollment":41},{"nctId":"NCT06316843","phase":"PHASE2","title":"Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2","status":"COMPLETED","sponsor":"Bateman Horne Center","startDate":"2023-10-15","conditions":"Long COVID, PASC Post Acute Sequelae of COVID 19","enrollment":59},{"nctId":"NCT03603405","phase":"PHASE1, PHASE2","title":"HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-02-28","conditions":"Glioblastoma, Anaplastic Astrocytoma","enrollment":62},{"nctId":"NCT03596086","phase":"PHASE1, PHASE2","title":"HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM","status":"RECRUITING","sponsor":"David Baskin MD","startDate":"2017-12-11","conditions":"Glioblastoma Multiforme, Astrocytoma, Grade III","enrollment":62},{"nctId":"NCT02831933","phase":"PHASE2","title":"Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma","status":"TERMINATED","sponsor":"Eric Bernicker, MD","startDate":"2017-02-15","conditions":"Lung Squamous Cell Carcinoma Stage IV, Nonsquamous Nonsmall Cell Neoplasm of Lung, Metastatic Uveal Melanoma","enrollment":11},{"nctId":"NCT01972035","phase":"PHASE2","title":"ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2014-08-01","conditions":"Transplantation Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections","enrollment":137},{"nctId":"NCT03541928","phase":"PHASE2","title":"Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-08-02","conditions":"High-risk Prostate Cancer, Prostate Cancer","enrollment":60},{"nctId":"NCT01364792","phase":"PHASE2","title":"To Rescue Cognition With Valaciclovir","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Schizophrenia, Psychosis","enrollment":24},{"nctId":"NCT01794897","phase":"PHASE4","title":"Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-02","conditions":"Herpes Simplex, Schizophrenia, Schizoaffective Disorder","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Experimental: Valacyclovir treatment","genericName":"Experimental: Valacyclovir treatment","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valacyclovir is a prodrug that is converted to acyclovir, which inhibits viral DNA polymerase to prevent herpesvirus replication. Used for Herpes simplex virus (HSV-1 and HSV-2) infection, Varicella-zoster virus (chickenpox and shingles) infection, Cytomegalovirus (CMV) infection prophylaxis in immunocompromised patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}